

**CHOATE, HALL & STEWART**

A PARTNERSHIP INCLUDING PROFESSIONAL CORPORATIONS

EXCHANGE PLACE

53 STATE STREET

BOSTON, MASSACHUSETTS 02109-2804

TELEPHONE (617) 248-5000 • FAX (617) 248-4000

WWW.CHOATE.COM

**TRANSMITTAL SHEET**Number of pages being sent 8 (including this page)**DATE:** October 31, 2003

Recipient	Company	Fax No.	Phone No.
1. Examiner D. Lukton	U.S. Patent and Trademark Office	1-703-746-5071	

**FROM:** C. Hunter Baker, M.D., Ph.D.**DIRECT DIAL:** (617) 248-5215

**REMARKS:** U.S Patent Application for "Inhibitors of Dipeptidyl-Aminopeptidase Type IV" by Bachovchin *et al.*  
U.S.S.N.: 08/950,542; Filed: October 15, 1997  
Attorney's Docket Number: 2002941-0051

**TIME SENT:** \_\_\_\_\_ **OPERATOR:** \_\_\_\_\_ **CLIENT NO.** 2002941-0051

Return by: Inter-office Mail \_\_\_\_\_ Hold for pick-up \_\_\_\_\_

THIS TRANSMITTAL IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS TRANSMITTAL IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE TRANSMITTAL TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY.

Received from &lt;617 248 4000&gt; at 10/31/03 10:21:16 AM [Eastern Standard Time]

**DRAFT**

**ATTORNEY'S DOCKET NUMBER: 2002941-0051**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Bachovchin <i>et al.</i>	Examiner:	Lukton, D.
Serial No.:	08/950,542	Art Unit:	1653
Filing Date:	October 15, 1997		
Title:	<i>Inhibitors of Dipeptidyl-aminopeptidase Type IV</i>		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**PROPOSED AMENDMENT**

Applicant submits this Amendment in the above-referenced case. Applicant respectfully requests entrance of the following amendments to the claims, and consideration of the following remarks.

**Amendments to the specification** begin on page 2 of this paper.

**Amendments to the claims** are reflected in the Listing of Claims that begins on page 3 of this paper.

**Remarks** begin on page 6 of this paper.

**DRAFT**